45-Year follow-up of hepatitis C virus infection in healthy young adults

Annals of Internal Medicine

Volumn 132, Issue 2, 2000, Pages 105-111

  Seeff, Leonard B ^a   Miller, Richard N ^a   Rabkin, Charles S ^a   Buskell Bales, Zelma ^a   Straley Eason, Kelle D ^a   Smoak, Bonnie L ^a   Johnson, Leslye D ^a   Lee, Stephen R ^a   Kaplan, Edward L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

EID: 0033970836     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-2-200001180-00003     Document Type: Article

References (43)

1. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology. 1983;85:439-62.
2. Kiyosawa K. Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-5.
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-6.
4. Seeff LB, Zimmerman HJ, Wright EC, Finkelstein JD, Garcia-Pont P, Greenlee HB, et al. A randomized, double-blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology. 1977;72:111-21.
5. Seeff LB, Wright EC, Zimmerman HJ, Hoofnagle JH, Dietz AA, Felsher BF, et al. Posttransfusion hepatitis, 1973-1975: a Veterans Administration Cooperative Study. In: Vyas GN, Cohen SN, Schmidt R, eds. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention Proceedings of the Second Symposium on Viral Hepatitis, University of California, San Francisco, March 16-19, 1978. Philadelphia: Franklin Institute Pr; 197:8371-81.
6. Alter HJ, Purcell RH, Feinstone SM, Holland PV, Morrow AG. Non-A/ non-B hepatitis: a review and interim report of an ongoing prospective study In: Vyas GN, Cohen SN, Schmidt R, eds. Viral Hepatitis A: Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention. Proceedings of the Second Symposium on Viral Hepatitis, University of California, San Francisco, March 16-19, 1978. Philadelphia: Franklin Institute Pr; 1978:359-69.
7. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, et al. Serum alanine aminotransferase of donors in relation to risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med. 1981;304:989-94
8. Knodell RG, Conrad ME, Ginsberg AL, Bell CJ. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet. 1976;1:557-61.
9. Kenny-Walsh E. Clinical outcomes after hepatitis C infect on from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228-33.
10. Dittmann S, Roggendorf M, Durkop J, Wiese M, Lorbeer B, Deinhardt F. Long-term persistence of hepatitis C virus antibodies in a single source outbreak. J Hepatol. 1991;13:323-7.
11. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology. 1991;14:969-74.
12. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis Looking back in the second decade. Ann Intern Med. 1993; 119:110-5.
13. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol. 1993;88:240-3.
14. Yano M, Yatsuhasi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long-term prognosis of hepatitis C virus infection in Japan. Gut. 1993; 34(Suppl):S13-516.
15. Denny FW, Wannamaker LW, Brink WR, Rammelkamp CH. Prevention of rheumatic fever, treatment of preceding streptococcic infection. JAMA. 1950;143:151-3.
16. Thomas RJ, Conwill DE, Morton DE, Brooks TJ, Holmes CK, Mahaffey WB. Penicillin prophylaxis for streptococcal infections in the United States Navy and Marine Corps recruit camps, 1951-1985 Rev Infect Dis 1988;10: 125-30.
17. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived f'om a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62.
18. Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang. 1994;66:122-9.
19. Bukh J, Purcell RH, Miller RH. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci U S A. 1992;89:187-91.
20. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.
21. Tobler LH, Busch MP, Wilber J, Dinello R, Quan S, Polito A, et al. Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion 1994;34:130-4.
22. Cuccherini B, Nussbaum SJ, Seeff LB, Lukacs L, Zimmerman HJ. Stability of aspartate aminotransferase and alanine aminotransferase activities. J Lab Clin Med. 1983;102:370-6.
23. Page WF, Mahan CM, Kang HK. Vital status ascertainment through the files of the Department of Veterans Affairs and the Social Security Administration. Ann Epidemiol. 1996;6:102-9.
24. Mehta CR, Patel NR, Gray R. Computing an exact confidence interval for the common odds ratio in several 2 × 2 contingency tables. Journal of the American Statistical Association. 1985;78:969-73.
25. Dean AG, Dean JA, Colombier D, Brendel KA, Smith DC, Burton AH, et al. Epi-Info, Version 6. A Word-Processing, Database, and Statistics Program for the Public Health on IBM-Compatible Microcomputers Atlanta, GA: Centers for Disease Control and Prevention; 1995.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-81.
27. SAS Users Guide. Statistics, Version 6. 4th ed. Cary, NC: SAS Institute; 1990.
28. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term morality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992; 327:1906-11.
29. Hyams KC, Struewing JP, Gray GC. Seroprevalence of hepatitis A, B, and C in a United States military recruit population. Mil Med. 1992;157:579-82.
30. Shakil AO, Contry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-7.
31. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, et al. Hepatitis C in asymptomatic blood donors Hepatology. 1997;26: 29S-33S.
32. McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C virus infection in the United Sates In: Rizzetto M, Purcell RH, Gerin JL, Verme G. eds. Viral Hepatitis and Liver Disease Proceedings of IC Triennial International Symposium on Viral Hepatits and Liver Disease, Rome, Italy, 21-25 April 1996. Turin: Edizioni Minerva Medica; 1997:267-70.
33. Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K. et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology. 1994;19: 1337-41.
34. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin L ver Dis. 1995;15:41-63.
35. Ries LA, Kosary CL, Hankey BF, Miller BA, Edwards BK, eds. Annual Cancer Statistics Review, 1973-1995. Bethesda, MD: U.S Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1998.
36. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Ergl J Med. 1999;340:745-50.
37. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, et al. A high prevalence of the antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;67:429-33.
38. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21:650-5.
39. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;2:1006-8.
40. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM. et al. Prevalence of antibodies to hepatitis C in Spanish patients witn hepato-cellular carcinoma and hepatic cirrhosis. Lancet. 1989;2:1004-6.
41. Moyer LA, Boyle CA, Pollock DA. Validity of death certificates for injury-related causes of death. Am J Epidemiol. 1989;130:1024-32.
42. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-32.
43. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3 Suppl 1):21S-28S.